Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study will aim to evaluate the efficacy of milnacipran in the treatment of pain due to osteoarthritis (OA), that is, to determine whether milnacipran provides superior efficacy to placebo in patients with OA. Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is currently approved in the United States in the treatment of major depressive disorder and fibromyalgia. There is increased evidence to suggest that SNRIs may be effective in the treatment of chronic pain conditions, such as OA.

The hypothesis in this study is that the survival time (time from randomization to loss of efficacy) of milnacipran group is superior to that of placebo group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Milnacipran for Chronic Pain in Knee Osteoarthritis

NCT01510457

Knee Osteoarthritis Degenerative Joint Disease Chronic Pain

COMPLETED PHASE4

"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

NCT01289236

Chronic Shoulder Pain

COMPLETED PHASE4

A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain

NCT00609557

Osteoarthritis Pain

COMPLETED PHASE4

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680

Osteoarthritis Knee Pain

COMPLETED PHASE3

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

NCT00211549

Osteoarthritis, Knee

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is a Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study. This means that, upon entry into the study, all subjects will enter an open-label period during which they will take milnacipran for 4 weeks. Subjects will taper their dose up to one 100mg tablet twice daily for a total of 200mg per day. After 4 weeks, the subject will return to the clinic and be re-evaluated.

Only subjects who meet certain criteria are then randomized to continue in the double-blind period of the study. Once a subject is randomized, he or she will take either milnacipran or placebo for another 4 weeks. Following the double-blind period, subjects will be tapered off the study medication and will receive a phone call once each week for 2 weeks for follow-up assessments.

Throughout the study, subjects will complete various questionnaires and other test procedures aimed at sub-typing subjects based on pain mechanisms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Milnacipran

If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).

Group Type EXPERIMENTAL

Milnacipran

Intervention Type DRUG

1 tablet (100mg) by mouth twice daily for 28 days

Placebo

If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1 tablet by mouth twice daily for 28 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Milnacipran

1 tablet (100mg) by mouth twice daily for 28 days

Intervention Type DRUG

Placebo

1 tablet by mouth twice daily for 28 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be 21-75 years of age and in good general medical and psychological health
* Be able to speak, read, write, and understand English, understand the consent form, complete study related procedures, and communicate with the study staff
* Have a negative urine pregnancy test at screening, and use appropriate birth control
* Have documented painful Osteoarthritis (OA) of at least one knee for at least 6 months; OA should be of Class I-III and meet the American College of Rheumatology (ACR) clinical classification criteria, defined as:

1. Knee pain and at least 3 of the following 6:

* Age \> 50
* Morning stiffness \< 30 minutes
* Crepitus on active motion
* Bony tenderness
* Bony enlargement
* No palpable warmth of synovium
2. The target joint must not contain any type of orthopedic and/or prosthetic device
* Have a target joint pain average of 5 days per week and have an average pain intensity of at least 4/10 on the 0-10 NRS over the last 24 hours prior to screening
* Have stable treatment modalities, e.g. acupuncture, physical therapy
* Be willing to stop taking Non-steroidal Anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study

Exclusion Criteria

* Are allergic or intolerant to SNRI; have a previous poor response to a SNRI for OA pain; are currently taking an SNRI or tricyclic antidepressant
* Have a body mass index (BMI) \>40 kg/m2
* Have an Hospital Anxiety and Depression Scale (HADS) score \>12 on either subscale or has an established history of major depressive disorder not controlled with medication
* Have significant pain outside the target knee, including significant hip or back pain. (Bilateral knee OA allowed.)
* Have pain affecting the target knee that is due to any other etiology than OA
* Have documented history of inflammatory arthritis including rheumatoid arthritis
* Have had local injections in target joint within the past 3 months prior to screening
* Have had oral or intramuscular corticosteroids within the past 30 days
* Have had worker's compensation claim, disability, or litigation
* Have a known history of uncontrolled narrow-angle glaucoma
* Have a known history of suicidal ideation
* Use monoamine oxidase inhibitors (MAOI) concomitantly
* Are allergic or intolerant to acetaminophen
* Using opioids 4 or more days per week during the month preceding the screening visit
* Have significant history or renal impairment/failure.

Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No